Two-year gap between biosimilar's approval and launch, report says

25 January 2017

Swiss pharma giant Novartis’ (NOVN: VX) subsidiary Sandoz might have received US approval for Erelzi (etanercept-szzs), a biosimilar to US biotech major Amgen’s (Nasdaq: AMGN) Enbrel (etanercept), in August 2016, but it will not go on sale until 2018 at the earliest.

That is according to the news source Reuters, which quotes the head of generics at Sandoz as admitting that patients will be kept waiting for its version of the big-selling psoriasis drug because of Amgen’s patent protection challenge.

Richard Francis told Reuters that the legal fight would go on for at least another year, accepting frustration at the situation but saying that Sandoz was “carving the landscape out” for biosimilars as it went.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK